Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: Pain. 2019 Mar;160(3):619–631. doi: 10.1097/j.pain.0000000000001442

Figure 3:

Figure 3:

Ednrb is methylated and transcriptionally silenced in 4T1-luc2 cells which can be reversed by decitabine treatment A) The promoter region of Ednrb is hypermethylated in the 4T1-luc2 cell line compared with control mammary gland tissue. B) mRNA expression levels of Ednrb in the 4T1-luc2 cell line and normal mammary gland. C) Decitabine treatment does not demethylate Ednrb in the 4T1-luc2 cells. D) mRNA expression levels of Ednrb in the 4T1-luc2 mammary carcinoma cells after 48 hours of 1 μM and 5 μM decitabine treatment compared with non-treated controls. F) Decitabine treatment demethylates Ednrb in vivo. E) Decitabine treatment leads to an increase in Ednrb mRNA expression in vivo. The gene is classified as fully methylated if the percentage of methylated reference is above 10. n=2–5. * P < 0.5; ** P < 0.01; Unpaired Student’s t-test or one-way ANOVA, Bonferroni post hoc test.